GlobeNewswire·Nov 13, 2026, 7:00 AM ET

Tvardi Therapeutics Announces Third Quarter 2026 Results and Provides Business Update

TVRD

Tvardi Therapeutics reported financial results for the third quarter ended September 30, 2026, with research and development expenses rising to $4.5 million from $3.6 million in the prior year period due to higher clinical costs for TTI-101.
General and administrative expenses decreased to $1.9 million from $2.3 million in the comparable 2025 period, primarily driven by lower professional fees.
The company reported a net loss of $6.1 million for the quarter, or $(0.48) per basic and diluted share, compared to a net loss of $5.5 million or $(0.59) per share in the same period in 2025.
Cash and cash equivalents stood at $22.3 million as of September 30, 2026, down from $30.8 million at the end of 2025, with management anticipating existing funds will cover operations into the third quarter of 2027.
Development plans for TTI-109 in ulcerative colitis are advancing based on positive Phase 1 healthy volunteer results showing STAT3 target engagement, subject to IND clearance and additional funding.
New preclinical data for TTI-101 demonstrated eightfold higher colon tissue exposure than plasma, normalized gene expression, modulated the gut microbiome, and prevented colon adenocarcinomas in chronic colitis models.
The Phase 1b/2 REVERT LIVER CANCER study for TTI-101 in hepatocellular carcinoma is on track to report topline data in the early first quarter of 2027.
Key upcoming milestones include the initiation of TTI-109 clinical trials in UC in 2027 pending regulatory clearance and funding, and the TTI-101 topline data release in early 2027.

Company: Tvardi Therapeutics
Keywords: Nasdaq:TVRD, Tvardi Therapeutics